Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-CIK for Relapsed Hematologic Malignancy
NCT03821519Phase 2Unknown
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of unmodified CIK in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), myelofibrosis (MF), myelodysplastic syndrome (MDS), sponsored by Papa Giovanni XXIII Hospital. Status: unknown.
02
Drugs
unmodified CIK
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)multiple myeloma (MM)myelofibrosis (MF)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03821519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821519.